Contents
Vol 12, Issue 525
Research Articles
- A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy.
- Pancreatitis is an FGF21-deficient state that is corrected by replacement therapy
Repression of FGF21 by the integrated stress response contributes to pancreatitis and can be reversed with either stress response inhibitors or FGF21.
- GDNF rescues the fate of neural progenitor grafts by attenuating Notch signals in the injured spinal cord in rodents
Glial-derived neurotrophic factor expression by grafted human neural progenitor cells enhances functional recovery after spinal cord injury.
- Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Proteolysis of platelet-bound GARP by thrombin liberates active TGF-β and contributes to cancer immune evasion in the tumor microenvironment.
- HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction
Histone deacetylase inhibition counteracts adverse left ventricular remodeling, improves pulmonary function, and reverses diastolic dysfunction.
- Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice
Unlike conventional influenza vaccines, mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in infant mice.
Editors' Choice
- Bystanders get in the game
Tissue-resident memory T cells respond in a nonspecific manner to reduce bacteria in the lungs of mice.
- Microglial sex affects Alzheimer’s disease
Sex-specific microglial microRNAs impact tau pathogenesis.
- A potential gut punch to gastric cancer
Combination chemotherapies that also inhibit the proline isomerase Pin1 may overcome the notorious drug resistance of gastric cancer.
Erratum
About The Cover

ONLINE COVER A Two-pronged Attack. The illustration shows two examples of combination immunotherapy using bispecific antibodies. Bispecific antibodies (three-sided shapes in the image) recognize the protein markers CD3 or CD28 on T cells (green) as well as tumor antigens, thus bringing T cells into proximity with ovarian or prostate cancer cells (pink and multicolored cells, respectively). Skokos et al. found that combining the anti-CD3 and anti-CD28 bispecific antibodies enhanced the killing activity of T cells and boosted the antitumor immune response in mice. [CREDIT: EMILIE CLARK]